Topics:
Lung Cancer • Radiation Oncology • Neuro-Oncology • Thoracic Malignancies • Medical Oncology
When do you consider using ALK targeted systemic therapy in lieu of WBRT or SRS for patients with metastatic ALK-positive NSCLC?
The Phase III J-ALEX study and two phase II studies seem to suggest favorable intracranial response rates for alectinib.
Answer from: Medical Oncologist at Academic Institution
The development of crizotinib in ALK positive patients led to incredible control rates systemically, but as is now well known, less ability to control CNS disease. When crizotinib was the sole FDA approved ALK directed therapy, this led to the concept of "treatment beyond progression" suc...
Sign in or Register to read more